Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study.


Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
29 04 2021
Historique:
pubmed: 23 10 2020
medline: 12 5 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Patients with schizophrenia (SCZ) represent a vulnerable population who have been understudied in COVID-19 research. We aimed to establish whether health outcomes and care differed between patients with SCZ and patients without a diagnosis of severe mental illness. We conducted a population-based cohort study of all patients with identified COVID-19 and respiratory symptoms who were hospitalized in France between February and June 2020. Cases were patients who had a diagnosis of SCZ. Controls were patients who did not have a diagnosis of severe mental illness. The outcomes were in-hospital mortality and intensive care unit (ICU) admission. A total of 50 750 patients were included, of whom 823 were SCZ patients (1.6%). The SCZ patients had an increased in-hospital mortality (25.6% vs 21.7%; adjusted OR 1.30 [95% CI, 1.08-1.56], P = .0093) and a decreased ICU admission rate (23.7% vs 28.4%; adjusted OR, 0.75 [95% CI, 0.62-0.91], P = .0062) compared with controls. Significant interactions between SCZ and age for mortality and ICU admission were observed (P = .0006 and P < .0001). SCZ patients between 65 and 80 years had a significantly higher risk of death than controls of the same age (+7.89%). SCZ patients younger than 55 years had more ICU admissions (+13.93%) and SCZ patients between 65 and 80 years and older than 80 years had less ICU admissions than controls of the same age (-15.44% and -5.93%, respectively). Our findings report the existence of disparities in health and health care between SCZ patients and patients without a diagnosis of severe mental illness. These disparities differed according to the age and clinical profile of SCZ patients, suggesting the importance of personalized COVID-19 clinical management and health care strategies before, during, and after hospitalization for reducing health disparities in this vulnerable population.

Identifiants

pubmed: 33089862
pii: 5935036
doi: 10.1093/schbul/sbaa158
pmc: PMC7665717
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

624-634

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Guillaume Fond (G)

FondaMental Academic Centers of Expertise for Schizophrenia, Créteil, France.
Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Vanessa Pauly (V)

FondaMental Academic Centers of Expertise for Schizophrenia, Créteil, France.
Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Marc Leone (M)

Aix-Marseille University, Assistance Publique Hôpitaux Universitaires de Marseille, Hôpital Nord, Service d'Anesthésie et de Réanimation, Marseille, France.

Pierre-Michel Llorca (PM)

FondaMental Academic Centers of Expertise for Schizophrenia, Créteil, France.
CMP B, CHU, EA 7280 Faculté de Médecine, Université d'Auvergne, Clermont-Ferrand, France.

Veronica Orleans (V)

Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Anderson Loundou (A)

Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Christophe Lancon (C)

FondaMental Academic Centers of Expertise for Schizophrenia, Créteil, France.
Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Pascal Auquier (P)

Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Karine Baumstarck (K)

Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Laurent Boyer (L)

FondaMental Academic Centers of Expertise for Schizophrenia, Créteil, France.
Aix-Marseille University, CEReSS-Health Service Research and Quality of Life Center, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH